PURPOSE: To assess the prognostic value of clinical, biologic, and morphologic data in peripheral neuroblastic tumors, International Neuroblastoma Staging System (INSS) stages 2A and 2B MYCN nonamplified, a multinational protocol entitled Localized Neuroblastoma European Study Group trial 94.01, with a trial of surgery as the only treatment, was initiated in 1995. We present the prognostic value of the revised International Neuroblastoma Pathology Classification (INPC) applied to the patients included in this protocol until its closure in 1999. MATERIALS AND METHODS: A total of 120 neuroblastic tumors from trial patients were reviewed by the European International Society of Pediatric Oncology neuroblastoma pathology panel and assigned to a favorable or unfavorable prognostic category according to the INPC guidelines. Overall survival and relapse-free survival (RFS) were estimated by the Kaplan-Meier method and compared by the log-rank test. RESULTS: A total of 115 of 120 patients were assessable and were assigned to the favorable (90 patients; 78.3%) or unfavorable (25 patients; 21.7%) category. The 60-month survival rate was 97.7% in favorable patients compared with 73.8% in unfavorable patients (P = .0002). RFS analysis showed a 60-month relapse rate of 13.4% and 32% in favorable and unfavorable patients (P < .025), respectively. Statistical analysis demonstrated a significant association of unfavorable INPC category and high lactate dehydrogenase level (P < .045). CONCLUSION: This European study shows for the first time that the INPC prognostic categorization has a significant impact on outcome prediction in INSS stage 2 localized peripheral neuroblastic tumors.
PURPOSE: To assess the prognostic value of clinical, biologic, and morphologic data in peripheral neuroblastic tumors, International Neuroblastoma Staging System (INSS) stages 2A and 2B MYCN nonamplified, a multinational protocol entitled Localized Neuroblastoma European Study Group trial 94.01, with a trial of surgery as the only treatment, was initiated in 1995. We present the prognostic value of the revised International Neuroblastoma Pathology Classification (INPC) applied to the patients included in this protocol until its closure in 1999. MATERIALS AND METHODS: A total of 120 neuroblastic tumors from trial patients were reviewed by the European International Society of Pediatric Oncology neuroblastoma pathology panel and assigned to a favorable or unfavorable prognostic category according to the INPC guidelines. Overall survival and relapse-free survival (RFS) were estimated by the Kaplan-Meier method and compared by the log-rank test. RESULTS: A total of 115 of 120 patients were assessable and were assigned to the favorable (90 patients; 78.3%) or unfavorable (25 patients; 21.7%) category. The 60-month survival rate was 97.7% in favorable patients compared with 73.8% in unfavorable patients (P = .0002). RFS analysis showed a 60-month relapse rate of 13.4% and 32% in favorable and unfavorable patients (P < .025), respectively. Statistical analysis demonstrated a significant association of unfavorable INPC category and high lactate dehydrogenase level (P < .045). CONCLUSION: This European study shows for the first time that the INPC prognostic categorization has a significant impact on outcome prediction in INSS stage 2 localized peripheral neuroblastic tumors.
Authors: Octavio Burgues; Samuel Navarro; Rosa Noguera; Antonio Pellín; Amparo Ruiz; Victoria Castel; Antonio Llombart-Bosch Journal: Virchows Arch Date: 2006-08-29 Impact factor: 4.064
Authors: Inge M Ambros; Gian-Paolo Tonini; Ulrike Pötschger; Nicole Gross; Véronique Mosseri; Klaus Beiske; Ana P Berbegall; Jean Bénard; Nick Bown; Huib Caron; Valérie Combaret; Jerome Couturier; Raffaella Defferrari; Olivier Delattre; Marta Jeison; Per Kogner; John Lunec; Barbara Marques; Tommy Martinsson; Katia Mazzocco; Rosa Noguera; Gudrun Schleiermacher; Alexander Valent; Nadine Van Roy; Eva Villamon; Dasa Janousek; Ingrid Pribill; Evgenia Glogova; Edward F Attiyeh; Michael D Hogarty; Tom F Monclair; Keith Holmes; Dominique Valteau-Couanet; Victoria Castel; Deborah A Tweddle; Julie R Park; Sue Cohn; Ruth Ladenstein; Maja Beck-Popovic; Bruno De Bernardi; Jean Michon; Andrew D J Pearson; Peter F Ambros Journal: J Clin Oncol Date: 2020-09-09 Impact factor: 44.544
Authors: A Gregorio; M V Corrias; R Castriconi; A Dondero; M Mosconi; C Gambini; A Moretta; L Moretta; C Bottino Journal: Histopathology Date: 2008-07 Impact factor: 5.087
Authors: M V Corrias; S Parodi; R Haupt; L Lacitignola; F Negri; A R Sementa; D Dau; F Scuderi; B Carlini; M Bianchi; F Casale; L Faulkner; A Garaventa Journal: Br J Cancer Date: 2008-01-08 Impact factor: 7.640
Authors: B De Bernardi; V Mosseri; H Rubie; V Castel; A Foot; R Ladenstein; G Laureys; M Beck-Popovic; A F de Lacerda; A D J Pearson; J De Kraker; P F Ambros; Y de Rycke; M Conte; P Bruzzi; J Michon Journal: Br J Cancer Date: 2008-09-02 Impact factor: 7.640